Protagonist Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Protagonist Therapeutics has been growing earnings at an average annual rate of 13.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 66.5% per year. Protagonist Therapeutics's return on equity is 31.4%, and it has net margins of 53.3%.
Anahtar bilgiler
13.5%
Kazanç büyüme oranı
23.0%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 66.5% |
| Özkaynak getirisi | 31.4% |
| Net Marj | 53.3% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey
Oct 16Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13
Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04Gelir ve Gider Dağılımı
Protagonist Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 319 | 170 | 40 | 127 |
| 31 Mar 24 | 315 | 162 | 40 | 126 |
| 31 Dec 23 | 60 | -79 | 33 | 120 |
| 30 Sep 23 | 0 | -140 | 32 | 121 |
| 30 Jun 23 | 0 | -138 | 31 | 116 |
| 31 Mar 23 | 1 | -140 | 30 | 117 |
| 31 Dec 22 | 27 | -127 | 32 | 126 |
| 30 Sep 22 | 35 | -130 | 32 | 135 |
| 30 Jun 22 | 45 | -133 | 33 | 146 |
| 31 Mar 22 | 47 | -122 | 32 | 138 |
| 31 Dec 21 | 27 | -126 | 27 | 126 |
| 30 Sep 21 | 24 | -108 | 25 | 107 |
| 30 Jun 21 | 27 | -81 | 23 | 86 |
| 31 Mar 21 | 31 | -70 | 20 | 80 |
| 31 Dec 20 | 29 | -66 | 19 | 75 |
| 30 Sep 20 | 26 | -65 | 18 | 71 |
| 30 Jun 20 | 17 | -73 | 17 | 76 |
| 31 Mar 20 | 2 | -83 | 17 | 71 |
| 31 Dec 19 | 0 | -77 | 16 | 65 |
| 30 Sep 19 | 0 | -74 | 15 | 63 |
| 30 Jun 19 | 2 | -66 | 15 | 54 |
| 31 Mar 19 | 22 | -45 | 14 | 57 |
| 31 Dec 18 | 31 | -39 | 14 | 59 |
| 30 Sep 18 | 40 | -28 | 13 | 57 |
| 30 Jun 18 | 43 | -24 | 12 | 56 |
| 31 Mar 18 | 31 | -31 | 12 | 50 |
| 31 Dec 17 | 20 | -37 | 12 | 46 |
| 30 Sep 17 | 9 | -45 | 11 | 43 |
| 30 Jun 17 | 0 | -48 | 10 | 38 |
| 31 Mar 17 | 0 | -40 | 9 | 31 |
| 31 Dec 16 | 0 | -38 | 7 | 26 |
| 30 Sep 16 | 0 | -32 | 5 | 21 |
| 30 Jun 16 | 0 | -28 | 4 | 19 |
| 31 Mar 16 | 0 | -24 | 4 | 15 |
| 31 Dec 15 | 0 | -15 | 3 | 12 |
Kaliteli Kazançlar: PTGX has high quality earnings.
Büyüyen Kar Marjı: PTGX became profitable in the past.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: PTGX has become profitable over the past 5 years, growing earnings by 13.5% per year.
Büyüme Hızlandırma: PTGX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Kazançlar vs. Sektör: PTGX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: PTGX's Return on Equity (31.4%) is considered high.